Cybrexa Therapeutics
Jaya Gautam has extensive work experience in the pharmaceutical industry. Starting in 1992, Jaya worked for Alcon Laboratories as a Senior Scientist until 1996. In 1997, Jaya joined Pfizer, Inc. as a Team Leader and remained there until 2012. During this time, Jaya gained leadership skills and expertise in team management. In 2012, Jaya joined Cubist Pharmaceuticals as Director of CMC Project Management until 2015. Jaya then joined Rhythm Pharmaceuticals Inc. in 2015 as an Executive Director and subsequently became the Vice President of Technical Operations from 2022 to 2023. Currently, Jaya works as the Senior Vice President of Technical Operations at Cybrexa Therapeutics, starting in 2023. Throughout Jaya's career, they have acquired a diverse range of skills and knowledge in the technical operations field within the pharmaceutical industry.
Jaya Gautam obtained a Ph.D in Pharmacy from Temple University between 1987 and 1992. Prior to that, between 1981 and 1985, Jaya Gautam attended Indian Institute of Technology, Varanasi, where they obtained a B. Pharm degree in Pharmacy.
This person is not in any offices
Cybrexa Therapeutics
1 followers
Cybrexa Therapeutics is developing an entirely new class of small molecule DNA repair inhibitors that directly target the tumor microenvironment. This approach leverages a novel tumor-localizing peptide technology developed by an internationally recognized research laboratory at Yale. Our approach will change the paradigm of drug delivery, and itwill greatly enhance the therapeutic index. It has the potential to re-define the definition of “drug-like,” which will unlock a vast array of molecules for clinical development. Our collection of tumor-localizing DNA repair inhibitors can be combined with numerous chemotherapies and also radiotherapy, allowing the safe delivery of higher drug doses, with enhanced efficacy.